All In Biotech

Drug Trial Radar · NCT07670650

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients With Stage 3 New Onset T1D, Recent Onset T1D, and Established T1D

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Nov 10, 2026

Primary completion

Mar 1, 2029

Study completion Sep 1, 2030

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
SAb Biotherapeutics, Inc.; Breakthrough T1D
First posted
Jun 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of SAB-142, a fully human anti-thymocyte globulin (h-ATG), in participants aged 5 to 40 years with Stage 3 type 1 diabetes (T1D). The study will enroll participants with recent-onset T1D (\>100 days to \<1 year from diagnosis) and established-onset T1D (≥1 year to ≤2 years from diagnosis) who retain residual beta-cell function as demonstrated by stimulated C-peptide levels \>0.2 nmol/L. Participants will be randomized in a 2:1 ratio to receive SAB-142 or placebo in addition to standard diabetes care. The primary objective is to determine whether SAB-142 preserves beta-cell function over 12 months as measured by stimulated C-peptide response during a mixed meal tolerance test (MMTT). External data from the SAB-142-201 SAFEGUARD study will be incorporated to include participants with new-onset T1D (\<100 days from diagnosis) in the primary efficacy analysis.

Conditions

  • Type 1 Diabetes (T1D)

Interventions

  • SAB-142Drug

    Treatment Period 1 (Induction) Day 1: SAB-142 0.5 mg/kg IV Day 2: SAB-142 2.0 mg/kg IV Treatment Period 2 (Month 6 Maintenance) Day 1: SAB-142 0.5 mg/kg IV Day 2: SAB-142 1.0 mg/kg IV Total induction dose: 2.5 mg/kg Total maintenance dose: 1.5 mg/kg

  • PlaceboDrug

    Placebo Comparator: Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT)Time frame: Dose administration to 12 Months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco Benioff Children's Hospital

    San Francisco, California · Not yet recruiting

  • Barbara Davis Center for Diabetes

    Aurora, Colorado · Not yet recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • IUH - Riley Hospital for Children - Riley Outpatient Center - Pediatric Diabetes & Endocrinology

    Indianapolis, Indiana · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.